Melanie Heinlein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Melanie Heinlein has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Amy S. Chuong
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
2 shared publicationsAna M. Meireles
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
2 shared publications- Antonio Rios
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
2 shared publications - Aviv Regev
Department of Biology, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications Avtar Singh
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
2 shared publications- Bo Li
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
2 shared publications
Latest Publications
- Open Access
- 26 February 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (7) , 1202
Author Correction: Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView
- 26 February 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (7) , 1202
Open AccessAuthor Correction: Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView
- Top Cited Papers
- 7 October 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (7) , 1091-1100
Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView
Optical pooled screening (OPS) is a scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture due to limitations associated with in situ sequencing of perturbation barcodes. Here, we develop PerturbView, an OPS technology that leverages in vitro transcription to amplify barcodes before in situ sequencing, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in induced pluripotent stem cell-derived neurons, primary immune cells and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF-κB signaling. Furthermore, we combine PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in situ screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications.
- 7 October 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (7) , 1091-1100
Top Cited PapersMultiplexed, image-based pooled screens in primary cells and tissues with PerturbView
Optical pooled screening (OPS) is a scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture due to limitations associated with in situ sequencing of perturbation barcodes. Here, we develop PerturbView, an OPS technology that leverages in vitro transcription to amplify barcodes before in situ sequencing, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in induced pluripotent stem cell-derived neurons, primary immune cells and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF-κB signaling. Furthermore, we combine PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in situ screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications.
- Open Access
- 16 February 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (4) , 491-507
Disruption of stem cell niche–confined R-spondin 3 expression leads to impaired hematopoiesis
Self-renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones, and locally by various niche-confined factors. R-spondin 3 (RSPO3) is one of the most potent enhancers of Wnt signaling, and its expression is usually restricted to the stem cell niche where it provides localized enhancement of Wnt signaling to regulate stem cell expansion and differentiation. Disruption of this niche-confined expression can disturb proper tissue organization and lead to cancers. Here, we investigate the consequences of disrupting the niche-restricted expression of RSPO3 in various tissues, including the hematopoietic system. We show that normal Rspo3 expression is confined to the perivascular niche in the bone marrow. Induction of increased systemic levels of circulating RSPO3 outside of the niche results in prominent loss of early B-cell progenitors and anemia but surprisingly has no effect on hematopoietic stem cells. Using molecular, pharmacologic, and genetic approaches, we show that these RSPO3-induced hematopoietic phenotypes are Wnt and RSPO3 dependent and mediated through noncanonical Wnt signaling. Our study highlights a distinct role for a Wnt/RSPO3 signaling axis in the regulation of hematopoiesis, as well as possible challenges related to therapeutic use of RSPOs for regenerative medicine.
- 16 February 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (4) , 491-507
Open AccessDisruption of stem cell niche–confined R-spondin 3 expression leads to impaired hematopoiesis
Self-renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones, and locally by various niche-confined factors. R-spondin 3 (RSPO3) is one of the most potent enhancers of Wnt signaling, and its expression is usually restricted to the stem cell niche where it provides localized enhancement of Wnt signaling to regulate stem cell expansion and differentiation. Disruption of this niche-confined expression can disturb proper tissue organization and lead to cancers. Here, we investigate the consequences of disrupting the niche-restricted expression of RSPO3 in various tissues, including the hematopoietic system. We show that normal Rspo3 expression is confined to the perivascular niche in the bone marrow. Induction of increased systemic levels of circulating RSPO3 outside of the niche results in prominent loss of early B-cell progenitors and anemia but surprisingly has no effect on hematopoietic stem cells. Using molecular, pharmacologic, and genetic approaches, we show that these RSPO3-induced hematopoietic phenotypes are Wnt and RSPO3 dependent and mediated through noncanonical Wnt signaling. Our study highlights a distinct role for a Wnt/RSPO3 signaling axis in the regulation of hematopoiesis, as well as possible challenges related to therapeutic use of RSPOs for regenerative medicine.
- 8 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (52)
Unresponsiveness to inhaled antigen is governed by conventional dendritic cells and overridden during infection by monocytes
Immunity to inhaled antigens is governed by inflammatory signals that alter the composition of DC subsets within the NALTs.
- 8 October 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (52)
Unresponsiveness to inhaled antigen is governed by conventional dendritic cells and overridden during infection by monocytes
Immunity to inhaled antigens is governed by inflammatory signals that alter the composition of DC subsets within the NALTs.
- 24 March 2016
- Published by Springer Nature in EMBO Reports
- Vol. 17 (5) , 724-738
The deubiquitinase Usp27x stabilizes the BH3‐only protein Bim and enhances apoptosis
Bim is a pro‐apoptotic Bcl‐2 family member of the BH3‐only protein subgroup. Expression levels of Bim determine apoptosis susceptibility in non‐malignant and in tumour cells. Bim protein expression is downregulated by proteasomal degradation following ERK‐dependent phosphorylation and ubiquitination. Here, we report the identification of a deubiquitinase, Usp27x, that binds Bim upon its ERK‐dependent phosphorylation and can upregulate its expression levels. Overexpression of Usp27x reduces ERK‐dependent Bim ubiquitination, stabilizes phosphorylated Bim, and induces apoptosis in PMA‐stimulated cells, as well as in tumour cells with a constitutively active Raf/ERK pathway. Loss of endogenous Usp27x enhances the Bim‐degrading activity of oncogenic Raf. Overexpression of Usp27x induces low levels of apoptosis in melanoma and non‐small cell lung cancer (NSCLC) cells and substantially enhances apoptosis induced in these cells by the inhibition of ERK signalling. Finally, deletion of Usp27x reduces apoptosis in NSCLC cells treated with an EGFR inhibitor. Thus, Usp27x can trigger via its proteolytic activity the deubiquitination of Bim and enhance its levels, counteracting the anti‐apoptotic effects of ERK activity, and therefore acts as a tumour suppressor. Synopsis This study shows that the deubiquitinase Usp27x binds to the pro‐apoptotic BH3‐only protein Bim and counter‐regulates Bim degradation through the Raf/ERK pathway. Levels of Usp27x determine the apoptotic outcome and might be relevant for the treatment response in such cells. The deubiquitinase Usp27x binds to phosphorylated Bim and stabilizes Bim by deubiquitination, counteracting Bim degradation by ERK. Loss of endogenous Usp27x enhances the Bim‐degrading activity of oncogenic Raf. Overexpression of Usp27x enhances apoptosis in cancer cells with a constitutively active Raf/ERK pathway; therefore, Usp27x may act as a tumour suppressor.
- 24 March 2016
- Published by Springer Nature in EMBO Reports
- Vol. 17 (5) , 724-738
The deubiquitinase Usp27x stabilizes the BH3‐only protein Bim and enhances apoptosis
Bim is a pro‐apoptotic Bcl‐2 family member of the BH3‐only protein subgroup. Expression levels of Bim determine apoptosis susceptibility in non‐malignant and in tumour cells. Bim protein expression is downregulated by proteasomal degradation following ERK‐dependent phosphorylation and ubiquitination. Here, we report the identification of a deubiquitinase, Usp27x, that binds Bim upon its ERK‐dependent phosphorylation and can upregulate its expression levels. Overexpression of Usp27x reduces ERK‐dependent Bim ubiquitination, stabilizes phosphorylated Bim, and induces apoptosis in PMA‐stimulated cells, as well as in tumour cells with a constitutively active Raf/ERK pathway. Loss of endogenous Usp27x enhances the Bim‐degrading activity of oncogenic Raf. Overexpression of Usp27x induces low levels of apoptosis in melanoma and non‐small cell lung cancer (NSCLC) cells and substantially enhances apoptosis induced in these cells by the inhibition of ERK signalling. Finally, deletion of Usp27x reduces apoptosis in NSCLC cells treated with an EGFR inhibitor. Thus, Usp27x can trigger via its proteolytic activity the deubiquitination of Bim and enhance its levels, counteracting the anti‐apoptotic effects of ERK activity, and therefore acts as a tumour suppressor. Synopsis This study shows that the deubiquitinase Usp27x binds to the pro‐apoptotic BH3‐only protein Bim and counter‐regulates Bim degradation through the Raf/ERK pathway. Levels of Usp27x determine the apoptotic outcome and might be relevant for the treatment response in such cells. The deubiquitinase Usp27x binds to phosphorylated Bim and stabilizes Bim by deubiquitination, counteracting Bim degradation by ERK. Loss of endogenous Usp27x enhances the Bim‐degrading activity of oncogenic Raf. Overexpression of Usp27x enhances apoptosis in cancer cells with a constitutively active Raf/ERK pathway; therefore, Usp27x may act as a tumour suppressor.